12:00 AM
 | 
Mar 14, 2002
 |  BC Extra  |  Company News

Seattle Genetics, Mabtech cancer MAb deal

Mabtech (Nacka, Sweden) granted SGEN an exclusive license to certain monoclonal antibodies that target cell surface molecules on a variety of...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >